ArriVent BioPharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr '26 Apr 24, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Market Cap	1,368	854	898	-	-
Market Cap Growth	146.73%	-4.88%	-	-	-
Enterprise Value	1,061	541.32	679.1	0	0
Last Close Price	30.95	20.12	26.64	-	-
PE Ratio	-	-4.66	-10.41	-	-
PB Ratio	4.28	2.78	3.49	-	-
P/TBV Ratio	3.87	2.52	3.25	-	-
P/FCF Ratio	-	-5.32	-12.79	-	-
P/OCF Ratio	-	-5.32	-12.79	-	-
EV/EBITDA Ratio	-	-3.05	-7.20	-	-
EV/EBIT Ratio	-	-3.05	-7.20	-	-
EV/FCF Ratio	-	-3.37	-9.67	-	-
Debt / Equity Ratio	-	0	0.00	0.00	0.00
Debt / EBITDA Ratio	0	0	0.00	0.00	0.00
Debt / FCF Ratio	0	0	0.00	-0.01	0.00
Net Debt / Equity Ratio	-1.02	-1.02	-0.85	0.98	1.92
Net Debt / EBITDA Ratio	1.76	1.76	2.32	2.01	4.42
Net Debt / FCF Ratio	1.95	1.95	3.12	2.69	3.74
Quick Ratio	12.06	12.06	12.67	12.94	19.54
Current Ratio	12.83	12.83	13.14	13.76	21.84
Return on Equity (ROE)	-58.88%	-58.88%	-39.36%	-64.18%	-56.99%
Return on Assets (ROA)	-58.39%	-58.39%	-43.06%	-43.12%	-20.19%
Return on Invested Capital (ROIC)	-1063.59%	-1063.59%	-469.29%	-1197.85%	-328.67%
Return on Capital Employed (ROCE)	-62.86%	-62.86%	-46.10%	-45.77%	-21.15%
Earnings Yield	-12.10%	-21.47%	-9.61%	-	-
FCF Yield	-	-18.80%	-7.82%	-	-
Buyback Yield / Dilution	-22.22%	-22.22%	-1369.88%	-67.64%	-
Total Shareholder Return	-22.22%	-22.22%	-1369.88%	-67.64%	-

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q